Wednesday, February 10, 2010, 8:30pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Rosetta Genomics, Ltd. (ROSG)

At 4:59AM SGT: 1.61 USD   0.00 (0.00%)  
 MORE ON ROSG 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Rosetta Genomics Ltd. (NGM:ROSG) Delayed quote dataEdit
Last Trade:1.61 USD
Trade Time:4:59AM SGT
Change: 0.00 (0.00%)
Prev Close:1.61
Open:N/A
Bid:N/A
Ask:1.86 x 1000
1y Target Est:N/A
Day's Range:N/A - N/A
52wk Range:1.59 - 3.80
Volume:0
Avg Vol (3m):90,725.4
Market Cap:22.82M
P/E (ttm):N/A
EPS (ttm):-0.87
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ROSG to Portfolio   Download Data

 HEADLINES 
•Rosetta Genomics Announces Issuance of Three U.S. Patents
Business Wire (Wed, Feb 3)
•Rosetta Genomics Fortifies Patent Position with U.S. Allowance of Claims Covering Human microRNAs miR-21 and hcmv-miR-UL112
Business Wire (Fri, Jan 29)
•Rosetta Genomics Ltd. Closes $5.1 Million Financing; Will Support Ongoing Development of microRNA-based Diagnostic Pipeline
Business Wire (Wed, Jan 20)
•Medifast, Rosetta Genomics: Biggest Price Decliners (MED, ROSG)
at The Wall Street Journal Online (Fri, Jan 15)
•LaBranche, Rosetta Genomics: Early Volume Plays
at TheStreet.com (Thu, Jan 14)
•Rosetta Genomics Ltd. to Raise $5.1 Million in Registered Direct Offering
Business Wire (Thu, Jan 14)
•Rosetta Announces that Johns Hopkins University Researchers Demonstrate miRview squamous Classifies Non-Small Cell Lung Cancer with Extremely High Degree of Accuracy
Business Wire (Wed, Jan 13)
•Rosetta Genomics Stockholders Elect Two New Directors at Annual Meeting
Business Wire (Wed, Dec 23)
•ROSETTA GENOMICS LTD Earnings, Business Update & Pipeline Progress Call scheduled for 8:30 am ET today
CCBN (Fri, Dec 18)
•Rosetta Genomics Reports Third Quarter Financial Results, Provides Business Update
Business Wire (Fri, Dec 18)
More Headlines for ROSG...
 ANALYST 
EPS Est (next year) () :N/A
EPS Est (in 2 years) () :N/A
Avg Rec (current)*:N/A
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices